(5HT) binding sites were analyzed in bovine brain membranes. The addition of either the 5-HT,,-selective drug 8-OH-DPAT (100 nM) or the 5-HT,,-selective drug mesulergine (100 nM) to the assay rkulted in a 5-l 0% decrease in specific 3H-5-HT binding. Scatchard analysis revealed that the simultaneous addition of both drugs decreased the B,,,,, of 3H-5-HT binding by lo-15% without affecting the & value (1.8 f 0.3 nM). Competition studies using a series of pharmacologic agents revealed that the sites labeled by 3H-5-HT in bovine caudate in the presence of 100 nM 8-OH-DPAT and 100 nM mesulergine appear to be homogeneous.
3H-5-Hydroxytryptamine (5HT) binding sites were analyzed in bovine brain membranes. The addition of either the 5-HT,,-selective drug 8-OH-DPAT (100 nM) or the 5-HT,,-selective drug mesulergine (100 nM) to the assay rkulted in a 5-l 0% decrease in specific 3H-5-HT binding. Scatchard analysis revealed that the simultaneous addition of both drugs decreased the B,,,,, of 3H-5-HT binding by lo-15% without affecting the & value (1.8 f 0.3 nM). Competition studies using a series of pharmacologic agents revealed that the sites labeled by 3H-5-HT in bovine caudate in the presence of 100 nM 8-OH-DPAT and 100 nM mesulergine appear to be homogeneous.
5-HT,, selective agents such as 8-OH-DPAT, ipsapirone, and buspirone display micromolar affinities for these sites. RU 24989 and (-)pindolol are approximately 2 orders of magnitude less potent at these sites than at 5-HT,, sites which have been identified in rat brain. Agents displaying nanomolar potencies for 5-HT,, sites such as mianserin and mesulergine are 2-3 orders of magnitude less potent at the 3H-5-HT binding sites in bovine caudate. In addition, both 5-HT,-and 5-HT,-selective agents are essentially inactive at these binding sites. These 3H-5-HT sites display nanomolar affinity for 5-carboxyamidotryptamine, 5-methoxytryptamine, metergoline, and 5-HT. Apparent K, values of 1 O-l 00 nhl are obtained for &LSD, RU 24969, methiothepin, tryptamine, methysergide, and yohimbine, whereas /-LSD and corynanthine are significantly less potent. In addition, these 3H-5-HT labeled sites are regulated by guanine nucleotides and calcium. Regional studies indicate that this class of sites is most dense in the basal ganglia but exists in all regions of bovine brain. These data therefore demonstrate the presence of a homogeneous class of 5-HT, binding sites in bovine caudate that is pharmacologically distinct from previously defined 5-HT,,, 5-HT,,, 5-HT,,, 5-HT,, and 5-HT, receptor subtypes.
We therefore suggest that this class of sites be designated the 5-HT,, subtype of binding sites labeled by Radioligand binding studies have identified multiple 5-hydroxytryptamine (5HT) receptors in the mammalian CNS. Initially, 2 main types of central 5-HT binding sites were charac-terized: 5-HT, sites labeled by 3H-5-HT and 5-HT, sites labeled by 3H-spiperone . More recently, 5-HT, binding sites labeled by 3H-5-HT have been shown to be heterogeneous (Pedigo et al., 1981; Schnellman et al., 1984; Asarch et al., 1985; Hoyer et al., 1985b; Peroutka, 1986) . To date, 3 distinct subtypes of the 5-HT, binding site have been identified. 5-HT,, sites can be directly labeled with 3H-8-hydroxy-N,iV-dipropyl-2-aminotetralin (8-OH-DPAT) (Gozlan et al., 1983; Hall et al., 1985; Peroutka, 1985 Peroutka, ,1986 , 3H-ipsapirone (Dompert et al., 1985) or 3H-l-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine (PAPP) (Ransom et al., 1986) and display nanomolar affinity for 8-OH-DPAT, ipsapirone, and buspirone. The 5-HT,, site appears to be limited to rat and mouse brain and displays high affinity for RU 24969 and (-)pindolol (Hoyer et al., 1985a; Heuring et al., 1986) . The 5-HT,, site is densely present in the choroid plexus but has also been identified in rat and porcine cortex (Pazos et al., 1984; Yagaloff and Hartig, 1985; Peroutka, 1986) . This site displays relatively high affinity for mesulergine, mianserin, and methysergide. Although all 5-HT, binding sites can be labeled by 3H-5-HT, each of the known subtypes displays a unique pharmacological profile.
The bovine caudate contains a high density of 3H-5-HT binding sites (Whitaker and Seeman, 1978; Peroutka and Snyder, 198 1) . Preliminary studies in this laboratory indicated that the specific 3H-5-HT binding in this region contained non-5-HT,, binding sites (Peroutka, 1985) . Therefore, the present study was performed in order to characterize these sites more extensively. The data show that the majority of 3H-5-HT binding sites in bovine caudate are homogeneous and distinct from the 5-HT,,, 5-HT,,, and 5-HT,, sites that have been described previously. Moreover, the site appears to exist in all bovine brain regions and is the most common 5-HT, binding site subtype in bovine brain.
Materials and Methods
Receptor binding assays were performed according to the methods of Peroutka (1985) . Briefly, adult bovine brains were obtained from a local slaughterhouse, dissected, immediately frozen, and stored at -70°C until needed. On the day of study, the tissue was defrosted and homogenized in 20 vol of 50 mM Tris-HCl (pH 7.7 at 25°C) using a Brinkmann Polytron and then centrifuged in an IEC B20A centrifuge at 49,000 x g for 10 min. The supematant was discarded, and the pellet was resuspended in the same volume of Tris-HCl buffer and incubated at 37°C for 10 min prior to a second centrifugation at 49,000 x g for 10 min. The final pellet was resuspended in 80 vol of Ttis-HCl buffer containing 10 WM pargyline, 4 mM calcium chloride and 0.1% ascorbic acid. For experiments concerning the effects of Ca2+, membranes were suspended in Caz+-free buffer. Ascorbic acid was added to all assays because of its recently demonstrated effects on 3H-5-HT stability (Peroutka et al., 1986~). The suspensions were immediately used in the Increasing concentrations of 5-HT, 8-OH-DPAT, or mesulergine were incubated with 2.0 nM 3H-5-HT and bovine caudate membranes as described in Materials and Methods. Data shown are the results of a single experiment performed in triplicate. Each experiment was repeated 3-6 times. A, Competition curves under standard assay conditions. B, Competition curves in the presence of 100 nM 8-OH-DPAT + 100 nM mesulergine. binding assay. In addition, the stability of the 3H-5-HT (i.e., >98% recovery) under standard assay conditions was documented by highpressure liquid chromatographic analysis as described previously .
Binding assays consisted of 0.1 ml 'H-ligand (final concentration, 1.6-2.0 nM 'H-5-HT), 0.1 ml buffer or displacing drug and 0.8 ml tissue suspension. Following incubation at 25°C for 30 min, the assays were rapidly filtered under vacuum through #32 glass fiber filters (Schleicher and Schuell; Keene, NH) with two 5 ml washes using 50 mM Tris-HCl buffer (pH 7.4). Radioactivity was measured by liquid scintillation spectroscopy in 5 ml of 3a70 scintillation cocktail (Research Products International, Mount Prospect, IL) at 56% efficiency. Specific binding was defined using 10 PM 5-HT for all experiments and represented 70-80% of total binding for 'H-5-HT. Drug displacement studies were analyzed by computer-assisted nonlinear regression analysis based on the methods of Munson and Rodbard (1980) and McPherson (1983) . Drug concentrations ranged from lo-l1 to 1O-4 M. All data were initially analyzed based on an assumption of a l-site model of "H-l&and binding. The data were then analyzed according to a 2-site model, and the results of the curve fitting were statistically compared to the 1 -site study by an F test. The 2-site model Competition studies were performed as described in Materials and Methods using 2 nM IH-5-HT. Computer-assisted analysis of the competition curves was performed according to the method of Munson and Rodbard (1980) and McPherson (1983) and was used to determine K, values and relative concentrations of each binding site.
Each curve was fit according to both a I-site and a 2-site model. When the 2-&e model gave a statistically better fit (p < 0.05), 2 K, values are given, with the percentage of each site reported in parentheses. Data given are the means + SE of 3 separate experiments, each performed in triplicate.
was accepted if the observed "fit" was significakly better @ < 0.05) than the "fit" observed using a l-site model of 3H-ligand binding. All other statistical comparisons were made using the standard t test.
Results 5-HT, S-OH-DPAT, and mesulergine competition studies with 3H-5-HT in bovine caudate Drug competition studies with 'H-5-HT were performed in bovine caudate as shown in Figure 1A . 5-HT competes for specific 3H-S-HT binding in a monophasic manner. It begins displacing specific 3H-5-HT binding at concentrations above lo-lo M and displaces 50% of binding at approximately 3 x 1O-9 M. All remaining specific binding is displaced by a concentration of 3 x lo-' M, and no further displacement is observed at concentrations as high as 1O-4 M. Therefore, 1O-5 M 5-HT was used to define nonspecific binding in all subsequent experiments. Computer-assisted nonlinear regression analysis of the data shows that the 5-HT competition curve is adequately described by a l-site model with a K, value of 2.9 + 1 nM (Table 1) .
In contrast, the 5-HT,,-selective drug 8-OH-DPAT and the 5-HT,,-selective drug mesulergine compete with 3H-5-HT in a biphasic manner (Fig. 1A) . Each drug competes for a small percentage of sites at nanomolar concentrations with a plateau observed at concentrations between 1 O-8 and 2 x 1 O-' M. g-OH-DPAT displaces remaining specific 3H-5-HT binding at concentrations above 2 x lo-' M. Similarly, mesulergine competes for all but approximately 10% of specific )H-5-HT binding at concentrations as high as 1O-4 M. Computer-assisted iterative curve-fitting analysis confirms the biphasic nature of the curves by best fitting each with a 2-site model (p < 0.0 1). 8-OH-DPAT recognizes 7 + 3% of total 'H-5-HT sites with high affinity (K, = 1.7 k 1 nM) and the remaining 93 f 3% of sites with relatively low affinity (K, = 1100 + 200 nM). Similarly, mesulergine recognizes a low percentage (8 f 2%) of high-affinity sites (K, = 0.91 ? 0.1 nM) and the remaining sites with relatively low affinity (K, = 10,000 f 2000 nM). Since these data suggest a low percentage of 5-HT,, and 5-HT,, sites in bovine caudate, all subsequent competition experiments were performed in the presence of 100 nM 8-OH-DPAT + 100 nM mesulergine. These drug concentrations are able to selectively block the low percentage of putative 5-HT,, and 5-HT,, sites without significantly affecting the remaining 3H-5-HT-labeled sites.
Under this condition, each of the 3 drugs appears to recognize a homogeneous population of specific 3H-5-HT binding sites (Fig. 1B) in bovine caudate. The competition curve for 5-HT is virtually identical to the curve observed under standard conditions (Fig. 1A) . By contrast, neither 8-OH-DPAT nor mesulergine displaced any specific 3H-5-HT binding at concentrations below lo-' M. Above concentrations of 2 x lo-' M, monophasic competition curves were observed with both drugs. Computer-assisted iterative curve fitting analysis confirmed that all 3 drug competition curves are adequately described by a 1 -site model of 'H-5-HT binding (Table 1) .
Saturation analysis of 3H-5-HT binding in bovine caudate
Saturation studies were performed with 3H-5-HT under standard assay conditions or in the presence of 100 nM 8-OH-DPAT + 100 nM mesulergine. 3H-5-HT displayed monophasic saturation in both the absence and presence of 100 nM g-OH-DPAT + 100 nM mesulergine. For the experiment shown in Figure 2A , Scatchard analysis demonstrated a single high-affinity (KD = 1.1 nM) component of 3H-5-HT binding (Fig. 2B) . However, in the presence of 100 nM 8-OH-DPAT + 100 nM mesulergine, 3H-5-HT labeled approximately 10% fewer binding sites (B,,, = 8.2 pmol/g tissue) than under standard assay conditions (9.0 pmol/g tissue), despite the fact that the KD value (1.5 nM) was not significantly different. Based on an analysis of 4 independent saturation studies in bovine caudate, 'H-5-HT displayed a KD value of 1.5 -t 0.2 nM and a B,,, of 8.7 f 0.3 pmol/g tissue under standard assay conditions. In the presence of 100 nM 8-OH-DPAT + 100 nM mesulergine, the K, was essentially unchanged (1.8 f 0.5 nM). However, the B,,, value (7.7 f 0.3 pmol/g tissue) was reduced significantly compared with control values (p < 0.05, t test). This 11% decrease in B,,, is consistent with the competition studies shown in Figure lA , which suggest that lO-15% of 'H-5-HT labeled sites in bovine caudate are displaced by 100 nM 8-OH-DPAT + 100 nM mesulergine.
Effect of nucleotides on -'H-5-HT binding in bovine caudate Nucleotide [GTP, GDP, Gpp(NH)p, GMP, ATP] interactions with specific 3H-5-HT binding in the presence of 100 nM g-OH-DPAT + 100 nM mesulergine were examined in bovine caudate membranes. GTP, GDP, and the nonmetabolizable GTP analog, Gpp(NH)p, significantly decreased specific 3H-5-HT binding (p < 0.01) at a concentration of 1O-3 M. Each nucleotide displaced 40-42% of specific 3H-5-HT binding in the bovine caudate. By contrast, 1O-3 M ATP and GMP had no significant effect on specific 3H-5-HT binding. A statistically significant difference exists between the effect ATP and those of GTP, GDP, or GppNHp (p < 0.0 1 for each comparison). Thus, modulation of specific 3H-5-HT binding sites in bovine caudate shows a rank order of sensitivity as previously demonstrated with other 5-HT binding site subtypes: GppNHp = GTP = GDP > GMP = ATP Mallat and Hamon, 1982; Battaglia et al., 1984; Schlegel and Peroutka, 1986 ).
Efect of 4 mM Caz+ on specific 3H-5-HT binding in bovine caudate In the presence of 100 nM 8-OH-DPAT + 100 nM mesulergine in bovine caudate membranes, 4 mM Ca2+ modulated specific XH-5-HT binding. At half-maximal 3H-5-HT concentrations (2.0 nM), the addition of 4 mM Caz+ to the binding assay caused an increase in total binding and a decrease in nonspecific binding, yielding an increase in specific 3H-5-HT binding. For example, 4 mM Ca*+ increased total binding by 7 * 1% and decreased nonspecific binding by 23 f 1% compared with values obtained using a Ca*+-free buffer. The net result was a significant increase (17 f 1%; p < 0.01) in the specific binding of 3H-5-HT to bovine caudate membranes in the presence of 100 nM g-OH-DPAT + 100 nM mesulergine. In addition, the sensitivity of 3H-5-HT binding to 1O-3 M GTP was significantly increased in the absence of Ca*+ . For example, 1O-3 M GTP decreased 3H-5-HT binding to 48 + 4% of control values in the absence of Ca*+. This effect was significantly greater (p < 0.01) than the effect observed in the presence of 4 mM Ca*+ (i.e., 60 + 1% of control values). By contrast, 1O-3 M ATP effects on 'H-5-HT binding were unaltered in the absence of Ca*+ (100 + 3% of control values). This pattern of Ca2+ sensitivity has been described previously for other 5-HT binding site subtypes (Mallat and Hamon, 1982; Hall et al., 1985; Blurton and Wood, 1986 ).
Regional analysis of 'H-.5-HT binding in the absence or presence of 100 nM 8-OH-DPAT and 100 nM mesulergine A concentration of 2.0 nM 3H-5-HT was used to define regional differences in total 3H-5-HT binding versus )H-5-HT binding in the presence of 100 nM 8-OH-DPAT + 100 nM mesulergine.
As noted in previous studies (Peroutka and Snyder, 198 l) , total 3H-5-HT binding was most dense in the substantia nigra, caudate, hippocampus, globus pallidus, and putamen (Table 2) . However, a distinct difference existed between regions in the amount of specific 3H-5-HT binding that remained in the presence of 100 nM 8-OH-DPAT + 100 nM mesulergine. In both caudate and globus pallidus, approximately 80% of specific )H-5-HT binding remained under this condition. By contrast, the majority of specific )H-5-HT binding in hippocampus was displaced by 100 nM 8-OH-DPAT + 100 nM mesulergine, with l 3H-5-HT Binding i n Bovi ne Caudate Binding assays were performed as described in Materials and Methods. Values given are the mean + SE of triplicate assays. Each experiment was repeated 3-4 times. Data are described as the percent of total specific binding observed using 2.0 nM )H-5-HT, where 100% = 3.8 + 0.3 pmol/g wet weight tissue.
only 30% of the original amount of specific 3H-5-HT binding remaining. In cortical areas, total specific 3H-5-HT binding ranged from 63 to 83% of caudate values. The amount of specific binding remaining in the presence of 100 nM 8-OH-DPAT + 100 nM mesulergine ranged from 57% in the temporal cortex to 77% in the frontal cortex. While the midbrain, brain stem, and cerebellar regions contained relatively low densities of total 3H-5-HT binding sites, they were similar in that they contained a very high percentage of sites not displaced by 100 nM 8-OH-DPAT + 100 nM mesulergine. The single exception was the medulla oblongata, in which only 35% of the specific 3H-5-HT binding remained in the presence of 8-OH-DPAT and mesulergine.
The choroid plexus was the only other brain region in which the majority of 'H-5-HT binding was displaced by 100 nM 8-OH-DPAT + 100 nM mesulergine. This finding is of interest since the choroid plexus is the region in which 5-HT,, binding R sites were first identified and characterized (Pazos et al., 1984; Yagaloff and Hartig, 1985) .
Drug interactions with 'H-5-HT binding sites in bovine caudate in the presence of 100 nM 8-OH-DPAT + 100 nM mesulergine To further characterize specific 3H-5-HT binding sites in bovine caudate, the interactions of a series of drugs were determined in competition studies with 'H-5-HT in the presence of 100 nM 8-OH-DPAT + 100 nM mesulergine. Figure 3A shows that several potent 5-HT,,-selective drugs are all relatively weak in competing for 3H-5-HT binding in bovine caudate. Although WB 4 10 1, buspirone and ipsapirone display nanomolar affinity for 5-HT,, sites in rat frontal cortex (Peroutka, 1986) , they compete for specific 3H-5-HT binding in bovine caudate at micromolar concentrations. Moreover, all 3 competition curves are monophasic below concentrations of 1 O-4 M. The Hill slope of WB 4101 competition with 'H-5-HT binding under these conditions was 1.1 + 0.02. K, values for each agent are presented in Table 3 .
By contrast, certain 5-HT,,-selective drugs were more potent competitors of 'H-5-HT binding sites in bovine caudate (Fig.  3B ). Computer analysis of RU 24969 interactions with the specific 3H-5-HT binding indicates that the data are adequately explained by a single population of binding sites with a K, value of 25 f 1 nM. The piperazines TFMPP and mCPP also displaced 'H-5-HT in a monophasic manner, with Hill slopes of 0.90 f 0.1 and 0.99 f 0.03, respectively. In addition, 2 relatively potent inhibitors of 5-HT,, sites in rat brain (Hoyer et al., 1985) , (-)pindolol and (-)propranolol, were more than loo-fold less potent at these 'H-5-HT binding sites in bovine brain (Table  3) .
Similarly, drugs reported to display relatively high affinity for the 5-HT,, binding site subtype (Pazos et al., 1984; Hoyer et al., 1985b) were markedly less potent in competing for 3H-5-HT binding in bovine caudate (Fig. 3C) . Methysergide is the most potent of the 5-HT,,-selective agents, with an IC,, value of approximately 100 nM and a Hill slope of 0.92 f 0.06. Mianserin was slightly less potent (K, = 480 nM; Hill slope = 1.04 + 0.03), while ketanserin and mesulergine were essentially inactive at the 3H-5-HT binding sites in bovine caudate.
The most potent agents at this class of 3H-5-HT binding sites 1200 + 100 8200 zk 600 > 100,000 9000 Ik 300 > 100,000 36 + 6 59 f 6 800 + 100 23,000 + 1000 36,000 + 5000 > 100,000 > 100,000
Binding assays using 1.6-2.0 no 3H-5-HT in the presence of 100 no 8-OH-DPAT + 100 no mesulergine were performed as described in Materials and Methods. IC,, values were determined by log-logit analysis. K, values were calculated according to the equation K, = IC,J( 1 + ['H-5-HTIIK,). The KD value for 'H-5-HT (1.8 nM) was derived from saturation experiments. Data given are means K, f SE of 3-6 experiments, each performed in triplicate.
were tryptamine derivatives (Table 3) . 5-CT had a K, of 0.75 f 0.1 nM, while 5-HT and 5-methoxytryptamine were slightly less potent. Ergot derivatives were also potent agents. Metergoline, d-LSD, and methysergide had K, values of 4.2 f 1,24 I~I 2, and 120 ? 20 nM, respectively. In addition, yohimbine, a putative alpha,-adrenergic agent, was moderately potent at this class of 3H-5-HT binding sites (K, = 59 + 6 nM). The binding site also displayed stereoselectivity, as demonstrated by the inactivity of l-LSD and corynanthine. Drugs that are potent agents at the putative 5-HT, receptor in the periphery (MDL 72222 and metoclopramide) were essentially inactive at this central 5-HT binding site. Finally, the biogenic amine neurotransmitters epinephrine and dopamine were inactive at this binding site.
Discussion
The major finding of the present study is that 3H-5-HT labels a population of binding sites in bovine caudate that is distinct from previously defined 5-HT,,, 5-HT,,, and 5-HT,, binding site subtypes labeled by 'H-5-HT. The binding of 3H-5-HT in bovine caudate is saturable, stereoselective, and displays high affinity (KD = 1.8 + 1 nM). Computer-assisted curve-fitting analysis suggests that these sites are homogeneous in bovine caudate. The most potent agents at these sites are tryptamines, ergots, RU 24969, and yohimbine. The sites are modified by guanine nucleotides and calcium. Regional studies suggest that this class of sites is present in all brain regions and that it represents the predominant form of 5-HT, binding site subtype in bovine brain. Since these pharmacological characteristics are distinct from previously described 5-HT, binding site subtypes, we suggest that these sites be designated 5-HT,, binding sites.
The initial studies of 3H-5-HT binding suggested that the radioligand labeled a heterogeneous population of binding sites (Bennett and Snyder, 1976; Fillion et al., 1978) . Nelson and colleagues were the first to suggest that at least 2 distinct subtypes could be identified using 3H-5-HT (Pedigo et al., 1981; Schnellman et al., 1984) . The 5-HT,, site was defined as having high affinity for spiperone, while the 5-HT,, site was defined as being relatively insensitive to this neuroleptic. More recently, the development of highly potent and binding site subtype selective agents has greatly facilitated the analysis of 5-HT, binding site subtypes (Middlemiss and Fozard, 1983) .
To date, the 5-HT,, site has been the most extensively characterized subtype of the 5-HT, class of binding sites (Table 4) . This site can be directly labeled by 3H-8-OH-DPAT (Gozlan et al., 1983; Hall et al., 1985; Peroutka, 1985 Peroutka, ,1986 , 3H-ipsapirone (Dompert et al., 1985) , 3H-PAPP (Ransom et al., 1986) , or 3H-WB 4 10 1 (Norman et al., 1985) . Unlike the 5-HT, binding site subtype described in the present report, the 5-HT,, site displays nanomolar affinity for 8-OH-DPAT, WB 4 10 1, and ipsapirone. In addition, the site is densely present in the hippocampus (Pazos and Palacios, 1985) .
A number of functional correlates have been proposed for this site. Neurophysiologically, 5-HT and 5-HT,, selective agents inhibit intrinsic raphe cell firing (VanderMaelen and Wilderman, 1984; Sprouse and Aghajanian, 1985; Trulson and Arasteh, 1985) and the population spike generated by hippocampal CA1 cells (Beck and Goldfarb, 1985; Peroutka et al., 1987) . In addition, both forskolin-induced stimulation of adenylate (De Vivo and Maayani, 1986) and drug-induced contractions of the canine basilar artery (Peroutka et al., 1986b; Taylor et al., 1986) appear to be modulated by 5-HT,, receptors. The 5-HT,, selective agents 8-OH-DPAT and 5-MeDMT produce the "5-HT behavioral syndrome" and at least 3 specific compolients of the syndrome (reciprocal forepaw treading, head-weaving, and tremor) have been attributed to stimulation ofthe 5-HT,, receptor (Tricklebank, 1985; Smith and Peroutka, 1986) . The 5-HT,, site has been labeled in rat brain with both 3H-5-HT (Sills et al., 1984; Blurton and Wood, 1986; Peroutka, 1986) and 1251-cyanopindolol (Hoyer et al., 1985a) . The 5-HT,, site reportedly displays extremely high affinity (0.38 nM) for RU 24969 and relatively low affinity for d-LSD and 8-OH-DPAT (Peroutka, 1986) . The site also has relatively high affinity (p& values < 100 nM) for (-)pindolol and (-)propranolol (Hoyer et al., 1985a) , drugs that are more than loo-fold less potent at the sites described in the present report. Conversely, mianserin is more than 2 orders of magnitude less potent at the 5-HT,, site than at the 3H-5-HT site described in the present report (Hoyer et al., 1985a; Peroutka, 1986) . The highest densities of 5-HT,, sites in rat brain are found in the caudate, superior colliculus, lateral geniculate, subiculum, and substantia nigra (Pazos and Palacios, 1985) . Extensive pharmacological studies have demonstrated that synaptosomal release of 5-HT can be modulated by 5-HT,, receptors in the rat Raiteri et al., 1986) . Interestingly, the 5-HT,, site appears to be present in only rat and mouse brain and not in other species, such as cow, guinea pig, frog, chicken, turtle, or human (Heuring et al., 1986) . The 5-HT,, site was first characterized in membranes from pig choroid plexus and cortex (Pazos et al., 1984) . The site has been labeled by 3H-5-HT, )H-mesulergine, and lZSI-LSD in the rat choroid plexus and may also be present in rat cortex (Pazos et al., 1984; Yagaloff and Hartig, 1985; Blurton and Wood, 1986; Peroutka, 1986) . Recent studies using rat choroid plexus have shown that the 5-HT,, site is linked to phosphatidylinositol turnover (Conn et al., 1986) . Pharmacologically, the 5-HT,, site displays nanomolar affinity for 5-HT, mesulergine, methysergide, and mianserin. By contrast, the sites described in the present report have significantly lower affinity for mesulergine, methysergide, and mianserin.
Previous investigators have also suggested that other binding sites can be labeled by 3H-5-HT. However, a class of sites with the pharmacological characteristics described in the present report has not yet been reported. For example, Robaut et al. (1986) identified a 3H-5-HT binding site in rat brain with a K, of 13 -Binding i n Bovi ne Caudate 15 nM that was insensitive to ergot derivatives and GTP. Similarly, solubilized 5-HT, binding sites apparently do not recognize the isomers of LSD (Allgren et al., 1985) . In addition, 2 other major types of 5-HT receptor have been described (Table 4 ). The 5-HT, receptor was first identified in brain membranes (Leysen et al., 1978) and displays high affinity for classical 5-HT antagonists and many neuroleptics . The receptor mediates head twitches in rats and mice, as well as 5-HT-induced contractions in many vascular systems (Leysen et al., 1984; Peroutka, 1984) . Finally, a 5-HT, receptor has been identified in the PNS (Bradley et al., 1986) . This putative serotonergic site has not been radiolabeled, and no correlate has been identified in the CNS. Nonetheless, the receptor displays high affinity for 5-HT and related analogs in physiological studies, and, unlike previously described 5-HT receptors, it can be blocked potently by drugs such as MDL 72222, metoclopramide, and (-)cocaine (Fozard, 1984) .
Thus, the pharmacological characteristics of the homogeneous class of binding sites labeled by 3H-5-HT in bovine caudate are distinct from the previously defined subtypes of the 5-HT, class of binding sites, as well as from 5-HT, and 5-HT, receptors. The 3H-5-HT sites in bovine caudate display high affinity for 5-HT, are saturable, and display stereoselectivity for the isomers of LSD and yohimbine. The most potent agents at these sites are tryptamine and ergot derivatives, as well as RU 24969. When 5-HT,, and 5-HT,, sites are pharmacologically blocked by the addition of 100 nM 8-OH-DPAT + 100 nM mesulergine, this class of sites can be demonstrated in all regions of bovine brain, with highest densities observed in the basal ganglia. The extensive pharmacological characterization of this homogeneous and unique class of binding sites in the bovine caudate enables us to suggest that this class of sites be designated the 5-HT,, subtype of binding sites labeled by 3H-5-HT. Rather than being a relatively localized binding site subtype (as are the 5-HT,, and 5-HT,, sites), this class of sites appears to exist in high density in many brain regions. Indeed, this class of sites is the predominant subtype of 5-HT, sites in bovine brain.
To date, 2 specific physiological effects of 5-HT have been described that may correlate with the novel 5-HT binding site described in the present report. In the first system, Charlton et al. (1986) described an inhibitory prejunctional "5-HT,-like" receptor in the isolated perfused rat kidney. This 5-HT receptor inhibited the stimulus-induced release of 3H-noradrenaline following sympathetic periteronal nerve stimulation to the kidney. 5-CT was the most potent agonist (IC,, = 1.8 nM), whereas 5-HT (IC,, = 45 nM) and RU 24969 (IC,, = 250 nM) were slightly less potent agonists. 8-OH-DPAT was totally inactive in this system. The effects of these agonists could be antagonized by methiothepin, metergoline, and methysergide but not by cyproheptadine, ketanserin, mesulergine, (-)propranolol, or (-t)pindolol. The authors concluded that the 5-HT receptor conformed to the general criteria of a "5-HT,-like" receptor but could not be correlated to either the 5-HT,,, 5-HT,,, or 5-HT,, subtypes. The effect of 5-HT and related agents in the isolated perfused rat kidney system is therefore quite similar to the drug potencies at the putative 5-HT,, binding site described here.
5-HT-induced contraction of the rat stomach fundus is a second physiological effect that does not appear to be mediated by previously described 5-HT receptor subtypes (Leysen and Tollenaere, 1982; Cohen and Wittenauer, 1986) . Interestingly, in the first major study of the system (Vane, 1959) , it was demonstrated that 5-HT and 5-MT were equipotent agents in the rat stomach fundus, while tyryptamine and N,N-DMT were 32-and 11 O-fold, respectively, less active than 5-HT. Similar rankorder potencies exist for these analogs at the putative 5-HT,, site (Table 3 ). More recently, Clineschmidt et al. (1985) concluded that the fundic 5-HT receptor resembled the "5-HT," binding site but that the heterogeneous nature of the radioligand binding precluded a more definitive correlation. Of note is the fact that yohimbine was a potent antagonist in this system, in agreement with its high affinity for the putative 5-HT,, site.
Clearly, more detailed future studies are needed to define functional correlates of the putative 5-HT,, binding site subtype. However, the present data demonstrates that 3H-5-HT labels a fourth subpopulation of binding sites that are distinct from the previously described 5-HT,,, 5-HT,,, and 5-HT,, sites. The characterization of this homogeneous population of 3H-5-HT labeled sites should facilitate the correlation of physiological actions with radioligand binding data. The identification and characterization of all physiologically relevant 5-HT receptors should, ultimately, elucidate the role of 5-HT in the CNS and PNS.
